Nordicus

Transforming Potential Into High Value Treatments

About this Event

Nordicus Partners Corp. [OTCQB: NORD] is helping to build the next generation of Nordic and U.S. high-growth biotech and healthcare companies by establishing a robust presence in the U.S. market.

Their model is unique in that this publicly traded company finds, accelerates, acquires and then exits after the company has reached a significant value inflection point. The Nordicus team is a blend of American and Nordic professionals, that uses its deep roots in the pharmaceutical industry to find the right company for a strategic acquisition of the program.

Nordicus looks for companies that are fully-funded through phase 1 clinical trials and target markets with significant unmet medical needs in potential multi-billion dollar markets. Two of their current portfolio companies include:
  • Oricidin, a biotech that has developed the first and only medical treatment for aggressive periodontitis. This disease affects 20-50% of the global population, creating a market worth nearly $10B.
  • Bio-Convert, which has developed the first and only approved drug for Oral Leukoplakia, reducing the risk of progression to oral cancer.

Watch our webinar with Nordicus CEO, Henrik Rouf, who will discuss these investments and other high impact opportunities they’re currently evaluating in Obsessive-Compulsive Disorder, Depression, PTSD, Parkinson’s, and Autoimmune disorders.

Video On Demand

– Recorded

February 19

SHARE THIS EVENT

All statements and expressions are the sole opinion of the company and are subject to change without notice. The Company is not liable for any investment decisions by its readers or subscribers. It is strongly recommended that any purchase or sale decision be discussed with a financial advisor, or a broker-dealer, or a member of any financial regulatory bodies. The information contained herein has been provided as an information service only. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. Investors are cautioned that they may lose all or a portion of their investment in this or any other company. Information contained herein contains “forward looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities and Exchange Act of 1934, as amended. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be “forward looking statements”. Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of words such as “expects”, “will”, “anticipates”, “estimates”, “believes”, or by statements indicating certain actions “may”, “could”, “should” or “might” occur.